Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study
Restricted accessResearch articleFirst published online September 16, 2016
Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study
INTRODUCTION: Inhaled nitric oxide (iNO) is the standard therapy for infants with persistent pulmonary hypertension of the newborn (PPHN). Recently, sildenafil has been evaluated as an alternative or adjunctive pulmonary vasodilator.
OBJECTIVE: To assess the effectiveness of adding sildenafil as an early adjunctive therapy together with iNO when treating newborns with PPHN and/or hypoxemic respiratory failure.
METHODS: This is a randomized placebo trial on newborns with gestational age > 34 weeks, postnatal age < 48 hours, and diagnosed with PPHN (oxygen index (OI) ≥ 20). Newborns were randomized to two groups: Group A- received oral sildenafil and iNO, and group B- received placebo and iNO. Initial and follow up echocardiography were performed over 14 days period.
RESULTS: A total of 24 newborns were recruited; 13 of them received sildenafil in addition to iNO and 11 received iNO and placebo. The most common causes of PPHN were meconium aspiration syndrome, pneumonia, and RDS. At the starting point, OI was marginally higher in the intervention group without statistical significance (29 vs 28). There were no differences between the two groups regarding surfactant administration, incidence of pneumothoraces, and the underlying causes of PPHN. Sildenafil or placebo treatment started within 12 hours after starting iNO (8 vs 6 hours).
CONCLUSION: Early use of oral sildenafil next to iNO in cases of PPHN was tolerated well by newborns and it did not show significant adverse effects. Further studies with a larger sample size is needed to assess its effecacy.
BodenG, BennettC.
The management of persistent pulmonary hypertension of the newborn. Paediatr Child Health2004;14:290–7.
2.
D’AlonzoGE, BarstRJ, AyresSM, et al.
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med1991;115:343–9.
3.
ChannickRN, NewhartJW, JohnsonFW, et al.
Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest1996;109:1545–9.
4.
TravadiJN, PatoleSK.
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol2003;36:529–35.
5.
KellyLK, PortaNF, GoodmanDM, CarrollCL, SteinhornRH.
Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr2002;141:830–2.
6.
SolaA, BaqueroH.
Sildenafil oral en medicina neonatal “Investigado para adultos, usado tambie”n por neonatos. An Pediatr (Barc)2007;66:167–76.
BuckML.
Sildenafil for the treatment of pulmonary hypertension in children. Pediatr Pharm2004;10:1–4.
9.
WeimannJ, UllrichR, HromiJ, et al.
Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology2000;92:1702–12.
10.
ShekerdemianLS, RavnHB, PennyDJ.
Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med2002;165:1098–102.
11.
SastryBKS, NarasimhanC, ReddyNK, et al.
A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J2002;54:410–14.
12.
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against use of Revatio [sildenafil] in children with pulmonary hypertension. 2012 Dec 13. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm.
13.
SinghTP, RohitM, GroverA, MalhotraS, VijayvergiyaR.
A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J2006;151:851;e1–5.
14.
MichelakisE, TymchakW, LienD, WebsterL, HashimotoK, ArcherS.
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation2002;105:2398–403.
15.
PrasadS, WilkinsonJ, GatzoulisMA.
Sildenafil in primary pulmonary hypertension. N Engl JMed2000;343:1342–43.
16.
EricksonS, ReyesJ, BohnD, et al.
Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am Coll Cardiol2002;39:402A (abstract).
17.
Fernández GonzálezaN, Rodríguez FernándezaA, Jerez RojasJ, et al.
Sildenafilo oral como tratamiento de un neonato con hipertensión pulmonar persistente. An Pediatr (Barc)2004;61:567–8.
18.
BoninoA, MoraesM, MortinottiM, et al.
Sildenafil ?‘una alternativa para el tratamiento de la hipertensión pulmonar persistente?Arch Pediatr Urug2005;76:130–4.
19.
NamachivayamP, TheilenU, ButtWW, CooperSM, PennyDJ, ShekerdemianLS.
Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med2006;174:1042–7.
20.
Herrera TorresR, Concha GonzalezEP, Holberto CastilloJ, et al.
Sildenafil oral como alternativa en el tratamiento de recién nacidos con hipertensión pulmonar persistente. Rev Mex Pediatr2006;73:159–63.
21.
BaqueroH, SolizA, NeiraF, VenegasME, SolaA.
Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics2006;117:1077–83.
22.
UsluS, KumtepeS, BulbulA, ComertS, BolatF, NuhogluA.
A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: A randomized controlled trial. J Trop Pediatr2011;57(4):245–50.
23.
Vargas-OrigelA, Gómez-RodriguezG, Aldana-ValenzuelaC, et al.
The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol2010;27:225–30.
24.
PeterM, MarciK, Sontag, Dunbar IvyD, Steven AbmanH.
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr2009;154(3):379–84,384.e1–2.
25.
KellerRL, HamrickSE, KittermanJA, FinemanJR, HawgoodS.
Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med2004;5:184–7.
26.
ShahPS, OhlssonA.
Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev2011;8:CD005494.
27.
EllsworthMA, HarrisMN, CareyWA, SpitzerAR, ClarkRH.
Off-Label Use of Inhaled Nitric Oxide after release of NIH consensus statement. Pediatrics2015;135(4)643–8.
28.
CabralJ, BelikJ.
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment. J Pediatr (Rio J)2013;89:226–42.
29.
SuBH, WatanabeT, ShimizuM, et al.
Doppler assessment of pulmonary artery pressure in neonates at risk of chroniclung disease. Arch Dis Child Fetal Neonatal Ed1997;77:F23–27.
30.
BergerM, HaimowitzA, Van ToshA, BerdoffRL, GoldbergE.
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol1985;6:359–65.
31.
Lemus-VarelaML, SolaA, Gómez-MedaBC.
Oral sildenafil citrate lacks genotoxicity and cytotoxicity in a primate model: Callithrix jacchus. J Perinatol2006;26:423–7.
32.
MarshCS, MardenB, NewsomR.
Severe retinopathy of prematurity [ROP] in a premature baby treated with sildenafil acetate [Viagra] for pulmonary hypertension. Br J Ophthalmol2004;88:306–7.
33.
AbramsD, Schulze-NeickI, MageeAG.
Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart2000;84:e4.
34.
TravardiJN, PatoleSK.
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatr Pulmonol2003;36:529–35.
35.
Oral sildenafil as an alternative treatment in the persistent pulmonary hypertension in newborns.
Rev Mex Pediatr2006;73:107–11.
36.
KhoranaM, YookaseamT, LayangoolT, KanjanapattanakulW, ParadeevisutH.
Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at queen Sirikit National Institute of Child Health. J Med Assoc Thai2011;94:S64–73.
37.
StockerC, PennyDJ, BrizardCP, CochraneAD, SotoR, ShekerdemianLS.
Intravenous sildenafil and inhaled nitric oxide: A randomized trial in infants after cardiac surgery. Intensive Care Med2003;29:1996–2003.
38.
MatamisD, PamporiS, PapathanasiouA, et al.
Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: Acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail2012;5(1):47–53.
